245 related articles for article (PubMed ID: 28640161)
1. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Archer DF; Labrie F; Bouchard C; Portman DJ; Koltun W; Cusan L; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
[TBL] [Abstract][Full Text] [Related]
5. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
6. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Bouchard C; Labrie F; Archer DF; Portman DJ; Koltun W; Elfassi É; Grainger DA; Ayotte N; Cooper TA; Martens M; Waldbaum AS; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Climacteric; 2015; 18(4):590-607. PubMed ID: 25511551
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
9. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
11. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
12. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Montesino M; Labrie F; Archer DF; Zerhouni J; Côté I; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Moyneur E; Balser J
Gynecol Endocrinol; 2016; 32(3):240-5. PubMed ID: 26634942
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
15. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
16. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Portman DJ; Goldstein SR; Kagan R
Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
18. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
19. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
20. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
